Javier San Martin

Chief Tech/Sci/R&D Officer chez ATHIRA PHARMA, INC.

Fortune : 6 M $ au 31/03/2024

58 ans

Health Technology

Consumer Services

Postes actifs de Javier San Martin

Sociétés	Poste	Début	Fin
ATHIRA PHARMA, INC.	Chief Tech/Sci/R&D Officer	15/04/2024	-

Sociétés	Poste	Début	Fin
ARROWHEAD PHARMACEUTICALS, INC.	Chief Tech/Sci/R&D Officer	18/11/2019	01/02/2024
ULTRAGENYX PHARMACEUTICAL INC.	Corporate Officer/Principal	01/12/2013	01/11/2019
AMGEN INC.	Corporate Officer/Principal	-	-
ELI LILLY AND COMPANY	Corporate Officer/Principal	-	-
ALDER BIOPHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-

University of Buenos Aires School of Medicine

Doctorate Degree

Internationale

Etats-Unis	7
Argentine	2

Opérationnelle

Corporate Officer/Principal	4
Chief Tech/Sci/R&D Officer	2
Doctorate Degree	1

Sectorielle

Health Technology	7
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	5
AMGEN INC.	Health Technology
ELI LILLY AND COMPANY	Health Technology
ARROWHEAD PHARMACEUTICALS, INC.	Health Technology
ULTRAGENYX PHARMACEUTICAL INC.	Health Technology
ATHIRA PHARMA, INC.	Health Technology

Entreprise privées	1
Lundbeck Seattle BioPharmaceuticals, Inc. Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.	Health Technology

Entreprise privées

Health Technology